Combination capecitabine/temozolomide (CAPTEM) in patients with neuroendocrine tumors (NETs): A single institution review.

e15184 Background: Neuroendocrine tumors (NETs) are commonly treated with multimodality therapy including surgery, somatostatin analogs, targeted agents, chemotherapy and others. The combination of capecitabine and temozolomide (CAPTEM) has been suggested as a treatment option for metastatic disease, however, prospective data is accruing. We sought to review our patient population to determine efficacy and safety of CAPTEM. Methods: This retrospective review included patients with NETs who had been seen at the Louisiana State University/Ochsner NET clinic. Appropriate institutional review board approval was obtained. Patients were identified via an eVelos database. Only NET patients who had been placed on CAPTEM as previously described and received at least one cycle were included for review. Those with inadequate records or without documented follow up were excluded. Response rate (RR) was evaluated by RECIST 1.1. Results: Thirty patients (17 female) were included for review. The median age of CAPTEM ini...